RESUMO
PURPOSE: As a general rule, homonymous hemianopic defects localize to the retrochiasmal visual pathway and a monocular defect localizes at or anterior to the chiasm. We report three patients with a monocular hemianopia on automated static perimetry following cerebral stroke. OBSERVATIONS: In this retrospective, consecutive case series, the charts of individuals presenting with stroke and monocular hemianopia were reviewed. Three individuals suffered cerebral stroke. Automated, static perimetry revealed a normal visual field in one eye and a monocular hemianopia in the other eye. No other neurologic, orbital or ocular causes were found. CONCLUSIONS AND IMPORTANCE: To our knowledge, this is the first report of this pattern of visual field loss following stroke, and we hypothesize that this phenomenon may be a unique feature of automated perimetry. Magnetic resonance imaging of the brain could be considered in patients with a monocular hemianopia on static perimetry.
RESUMO
The number of patients undergoing percutaneous coronary intervention (PCI) who mandate additional oral anticoagulant therapy has been increasing. Dual antiplatelet therapy (DAPT) is associated with reduced ischemic events including stent thrombosis, myocardial infarction and stroke following PCI. However, the tradeoff is an increased risk for bleeding while on DAPT. The addition of a novel oral anticoagulant (NOAC) further increases the likelihood of bleeding while on antiplatelet therapy. Thus, the overall risks and benefits for each patient undergoing PCI on NOAC must be assessed and therapy individualized to ensure optimal therapy for each unique situation. Patients on NOAC undergoing PCI should undergo routine assessment with intravascular imaging as the role of high-risk lesion-related features have increased importance prior to determining optimal duration of treatment with DAPT. We review the best practices for the pharmacologic management of patients requiring anticoagulation with NOAC who are treated with PCI and require antiplatelet therapy.
RESUMO
The number of patients undergoing percutaneous coronary intervention (PCI) who mandate additional oral anticoagulant therapy has been increasing. Dual antiplatelet therapy (DAPT) is associated with reduced ischemic events including stent thrombosis, myocardial infarction and stroke following PCI. However, the tradeoff is an increased risk for bleeding while on DAPT. The addition of a novel oral anticoagulant (NOAC) further increases the likelihood of bleeding while on antiplatelet therapy. Thus, the overall risks and benefits for each patient undergoing PCI on NOAC must be assessed and therapy individualized to ensure optimal therapy for each unique situation. Patients on NOAC undergoing PCI should undergo routine assessment with intravascular imaging as the role of high-risk lesion-related features have increased importance prior to determining optimal duration of treatment with DAPT. We review the best practices for the pharmacologic management of patients requiring anticoagulation with NOAC who are treated with PCI and require antiplatelet therapy.